Showing results (171-180 of 225) with videos related to

Sort By:
Pageof 23
Cancer Treatment and Research Communications|November 3, 2019
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective studySebastiano Buti, Melissa Bersanelli, Alessandro Viansone, et al.
Clinical Genitourinary Cancer|June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or CabozantinibRoberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
Targeted Oncology|August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World StudyMatteo Santoni, Francesco Massari, Enrique Grande, et al.
Tumori|November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
International Journal of Molecular Sciences|January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
The International Journal of Biological Markers|January 14, 2017
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastasesEnrico Munari, Luca Cima, Francesco Massari, et al.
Urologic Oncology|June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancerRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
International Urology and Nephrology|April 9, 2026
Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancerPierluigi Russo, Nazario Foschi, Nicolò Lentini, et al.
Cancers|November 27, 2024
Relationship Between Loss of Y Chromosome and Urologic Cancers: New Future PerspectivesPierluigi Russo, Francesco Pio Bizzarri, Giovanni Battista Filomena, et al.
Pageof 23